{"id":68296,"date":"2026-04-09T12:10:19","date_gmt":"2026-04-09T06:40:19","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=68296"},"modified":"2026-04-09T12:10:21","modified_gmt":"2026-04-09T06:40:21","slug":"why-is-zydus-lifesciences-share-price-falling","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/why-is-zydus-lifesciences-share-price-falling\/","title":{"rendered":"Why Is Zydus Lifesciences Share Price Falling? Key Reasons And Share Price Target"},"content":{"rendered":"<p>Zydus Lifesciences is trading at Rs 860, down -20% from its 52-week high of Rs 1,300. The sustained decline in the Zydus Lifesciences share price reflects a combination of company-specific headwinds, sector pressures, and the broader macro overhang from the US 26% reciprocal tariff on Indian goods announced on April 2, 2026. This article explains every key reason behind the Zydus Lifesciences share price falling and provides a structured share price target for 2026.<\/p><div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/why-is-zydus-lifesciences-share-price-falling\/#About_Zydus_Lifesciences\" title=\"About Zydus Lifesciences\">About Zydus Lifesciences<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/why-is-zydus-lifesciences-share-price-falling\/#Why_Is_Zydus_Lifesciences_Share_Price_Falling_Key_Reasons\" title=\"Why Is Zydus Lifesciences Share Price Falling? Key Reasons\">Why Is Zydus Lifesciences Share Price Falling? Key Reasons<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/why-is-zydus-lifesciences-share-price-falling\/#1_US_Generics_Pricing_Pressure_Intensifying\" title=\"1. US Generics Pricing Pressure Intensifying\">1. US Generics Pricing Pressure Intensifying<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/why-is-zydus-lifesciences-share-price-falling\/#2_Asacol_HD_Exclusivity_Cliff\" title=\"2. Asacol HD Exclusivity Cliff\">2. Asacol HD Exclusivity Cliff<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/why-is-zydus-lifesciences-share-price-falling\/#3_Insulin_Aspart_Approval_Timeline_Uncertainty\" title=\"3. Insulin Aspart Approval Timeline Uncertainty\">3. Insulin Aspart Approval Timeline Uncertainty<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/why-is-zydus-lifesciences-share-price-falling\/#4_High-Value_Product_Cliff_Post_Key_Exclusivities\" title=\"4. High-Value Product Cliff Post Key Exclusivities\">4. High-Value Product Cliff Post Key Exclusivities<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/why-is-zydus-lifesciences-share-price-falling\/#5_Premium_Valuation_vs_Indian_Pharma_Peers\" title=\"5. Premium Valuation vs. Indian Pharma Peers\">5. Premium Valuation vs. Indian Pharma Peers<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/why-is-zydus-lifesciences-share-price-falling\/#Zydus_Lifesciences_Latest_News_That_Impacted_the_Stock\" title=\"Zydus Lifesciences Latest News That Impacted the Stock\">Zydus Lifesciences Latest News That Impacted the Stock<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/why-is-zydus-lifesciences-share-price-falling\/#Financial_Performance_Analysis\" title=\"Financial Performance Analysis\">Financial Performance Analysis<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/why-is-zydus-lifesciences-share-price-falling\/#Technical_Signals_What_the_Charts_Are_Saying\" title=\"Technical Signals: What the Charts Are Saying\">Technical Signals: What the Charts Are Saying<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/why-is-zydus-lifesciences-share-price-falling\/#Market_Sentiment_Institutional_Positioning\" title=\"Market Sentiment &amp; Institutional Positioning\">Market Sentiment &amp; Institutional Positioning<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/why-is-zydus-lifesciences-share-price-falling\/#Future_Outlook_Can_Zydus_Lifesciences_Recover\" title=\"Future Outlook: Can Zydus Lifesciences Recover?\">Future Outlook: Can Zydus Lifesciences Recover?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/why-is-zydus-lifesciences-share-price-falling\/#Zydus_Lifesciences_Share_Price_Target\" title=\"Zydus Lifesciences Share Price Target\">Zydus Lifesciences Share Price Target<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/why-is-zydus-lifesciences-share-price-falling\/#Short-Term_Target_3%E2%80%936_Months\" title=\"Short-Term Target (3\u20136 Months)\">Short-Term Target (3\u20136 Months)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/why-is-zydus-lifesciences-share-price-falling\/#12-Month_Analyst_Target\" title=\"12-Month Analyst Target\">12-Month Analyst Target<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/why-is-zydus-lifesciences-share-price-falling\/#Long-Term_Target_2027%E2%80%932028\" title=\"Long-Term Target (2027\u20132028)\">Long-Term Target (2027\u20132028)<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/why-is-zydus-lifesciences-share-price-falling\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/why-is-zydus-lifesciences-share-price-falling\/#FAQs\" title=\"FAQs\">FAQs<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/why-is-zydus-lifesciences-share-price-falling\/#Q1_Why_is_Zydus_Lifesciences_share_price_falling\" title=\"Q1. Why is Zydus Lifesciences share price falling?\">Q1. Why is Zydus Lifesciences share price falling?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/why-is-zydus-lifesciences-share-price-falling\/#Q2_What_is_the_Zydus_share_price_target_for_2026\" title=\"Q2. What is the Zydus share price target for 2026?\">Q2. What is the Zydus share price target for 2026?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/univest.in\/blogs-2\/why-is-zydus-lifesciences-share-price-falling\/#Q3_What_is_Zyduss_insulin_aspart_biosimilar\" title=\"Q3. What is Zydus&#8217;s insulin aspart biosimilar?\">Q3. What is Zydus&#8217;s insulin aspart biosimilar?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/univest.in\/blogs-2\/why-is-zydus-lifesciences-share-price-falling\/#Q4_What_is_Zyduss_US_business_revenue_contribution\" title=\"Q4. What is Zydus&#8217;s US business revenue contribution?\">Q4. What is Zydus&#8217;s US business revenue contribution?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-23\" href=\"https:\/\/univest.in\/blogs-2\/why-is-zydus-lifesciences-share-price-falling\/#Q5_What_is_Zyduss_promoter_holding\" title=\"Q5. What is Zydus&#8217;s promoter holding?\">Q5. What is Zydus&#8217;s promoter holding?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-24\" href=\"https:\/\/univest.in\/blogs-2\/why-is-zydus-lifesciences-share-price-falling\/#Q6_What_is_Zyduss_EBITDA_margin\" title=\"Q6. What is Zydus&#8217;s EBITDA margin?\">Q6. What is Zydus&#8217;s EBITDA margin?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-25\" href=\"https:\/\/univest.in\/blogs-2\/why-is-zydus-lifesciences-share-price-falling\/#Q7_What_could_trigger_a_Zydus_share_price_recovery\" title=\"Q7. What could trigger a Zydus share price recovery?\">Q7. What could trigger a Zydus share price recovery?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-26\" href=\"https:\/\/univest.in\/blogs-2\/why-is-zydus-lifesciences-share-price-falling\/#Q8_Is_Zydus_a_good_long-term_investment\" title=\"Q8. Is Zydus a good long-term investment?\">Q8. Is Zydus a good long-term investment?<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-27\" href=\"https:\/\/univest.in\/blogs-2\/why-is-zydus-lifesciences-share-price-falling\/#Recent_Article\" title=\"Recent Article\">Recent Article<\/a><\/li><\/ul><\/nav><\/div>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"About_Zydus_Lifesciences\"><\/span><strong>About Zydus Lifesciences<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p><a href=\"https:\/\/univest.in\/user\/log-in\">Click Here \u2013 Get Free Investment Predictions<\/a><\/p><p>Zydus Lifesciences (NSE: ZYDUSLIFE) is a leading listed company in the Pharma sector with a market capitalisation of Rs 86,000 Cr. The stock trades at approximately 26x P\/E and 4.8x price-to-book. Its 52-week range is Rs 820 to Rs 1,300, and the current price of Rs 860 sits near the lower end of that range.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Why_Is_Zydus_Lifesciences_Share_Price_Falling_Key_Reasons\"><\/span><strong>Why Is Zydus Lifesciences Share Price Falling? Key Reasons<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p><a href=\"https:\/\/univest.in\/user\/log-in\">Tap to Access Best Research Pieces on Univest<\/a><\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"1_US_Generics_Pricing_Pressure_Intensifying\"><\/span><strong>1. US Generics Pricing Pressure Intensifying<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>The US generics market has seen accelerated pricing pressure from consolidated generic drug purchasers (Walgreens Boots Alliance, CVS Health, and Rite Aid successors) who negotiate harder with every annual contract renewal. Zydus Lifesciences earns approximately 38% of its consolidated revenue from the US market. Price erosion of 4-6% per year on the base US business \u2014 net of new product launches \u2014 compresses the revenue growth trajectory even when volumes are healthy.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"2_Asacol_HD_Exclusivity_Cliff\"><\/span><strong>2. Asacol HD Exclusivity Cliff<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Zydus had been earning meaningful exclusive revenue from mesalamine (Asacol HD 800mg), a drug used in ulcerative colitis, under a First-to-File patent settlement. This exclusivity period is ending, and multiple generics are entering the market. The revenue impact is estimated at Rs 400-500 crore on an annualised basis \u2014 a meaningful hole in Zydus&#8217;s US revenue mix that Q4 FY26 results will begin to reflect.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"3_Insulin_Aspart_Approval_Timeline_Uncertainty\"><\/span><strong>3. Insulin Aspart Approval Timeline Uncertainty<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Zydus&#8217;s biosimilar insulin aspart (ZyTUS-B) in the US represents a significant long-term opportunity but faces a longer-than-expected FDA approval timeline. The US insulin biosimilar market is large \u2014 the branded market is over $4 billion \u2014 but regulatory pathways for biosimilars are complex and subject to delay. Any pushback in approval extends the period during which investors are waiting for this catalyst.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"4_High-Value_Product_Cliff_Post_Key_Exclusivities\"><\/span><strong>4. High-Value Product Cliff Post Key Exclusivities<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>The transition from high-margin first-wave exclusivity products to the base generics business involves a revenue mix deterioration that compresses overall EBITDA margins. Zydus&#8217;s EBITDA margin declined from 27.1% to 25.4% in Q3 FY26, and Q4 FY26 guidance suggests further compression to approximately 24-25% as the exclusivity cliff bites.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"5_Premium_Valuation_vs_Indian_Pharma_Peers\"><\/span><strong>5. Premium Valuation vs. Indian Pharma Peers<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>At 26x P\/E, Zydus commands a significant premium over most large-cap Indian generic pharma peers. This premium was justified by high-value US exclusivities and the growth trajectory of its specialty and biologics pipeline. As exclusivities wind down and the specialty pipeline faces delays, the premium is difficult to sustain at the same level.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Zydus_Lifesciences_Latest_News_That_Impacted_the_Stock\"><\/span><strong>Zydus Lifesciences Latest News That Impacted the Stock<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p><strong>Q3 FY26 results (February 2026): <\/strong>Revenue Rs 5,142 crore (+12% YoY), PAT Rs 894 crore. US business grew 18% CC \u2014 strong, but guidance cautious for Q4.<\/p><p><strong>February 2026: <\/strong>Asacol HD (mesalamine) exclusivity period ending \u2014 generics competition enters. Revenue impact Rs 400-500 crore annualised.<\/p><p><strong>March 2026: <\/strong>Biosimilar saroglitazar launch in the US faces delayed FDA approval \u2014 timeline pushed to H1 FY27.<\/p><p><strong>April 2026: <\/strong>US pharma sector FII outflow. Generics pricing pressure macro continues.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Financial_Performance_Analysis\"><\/span><strong>Financial Performance Analysis<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>Zydus Lifesciences&#8217;s quarterly numbers provide important context for the share price decline. The table below highlights key metrics versus the year-ago quarter.<\/p><figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Key Metric<\/strong><\/td><td><strong>Latest Quarter<\/strong><\/td><td><strong>Year-Ago Quarter<\/strong><\/td><td><strong>YoY Change<\/strong><\/td><\/tr><tr><td>Revenue<\/td><td>Rs 5,142 Cr<\/td><td>Rs 4,590 Cr<\/td><td>+12.0%<\/td><\/tr><tr><td>Net Profit<\/td><td>Rs 894 Cr<\/td><td>Rs 896 Cr<\/td><td>-0.2%<\/td><\/tr><tr><td>EBITDA Margin<\/td><td>25.4%<\/td><td>27.1%<\/td><td>-170 bps<\/td><\/tr><tr><td>US Business Rev<\/td><td>Rs 1,980 Cr<\/td><td>Rs 1,678 Cr<\/td><td>+18.0%<\/td><\/tr><\/tbody><\/table><\/figure><p>If you want to track Zydus Lifesciences&#8217;s financial metrics in real time, check the <a href=\"https:\/\/univest.in\/screeners\">Univest Screener<\/a><\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Technical_Signals_What_the_Charts_Are_Saying\"><\/span><strong>Technical Signals: What the Charts Are Saying<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>Zydus is trading at Rs 860, near its 52-week low of Rs 820. Support at Rs 800-820. Resistance at Rs 980-1,050. RSI at 38 is approaching oversold but no technical reversal signal yet.<\/p><p>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Zydus Lifesciences&#8217;s live price.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Market_Sentiment_Institutional_Positioning\"><\/span><strong>Market Sentiment &amp; Institutional Positioning<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>Promoter (Pankaj Patel family) holds 74.9% \u2014 stable and high conviction. FII holding at 16.2% \u2014 moderate and stable. DII at 9.8%. The stock lacks a major institutional catalyst to drive recovery without a product pipeline trigger.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Future_Outlook_Can_Zydus_Lifesciences_Recover\"><\/span><strong>Future Outlook: Can Zydus Lifesciences Recover?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>Zydus&#8217;s recovery is a product pipeline story. Insulin aspart approval in the US would be a major positive catalyst. The India business \u2014 growing at 12-14% \u2014 provides a steady earnings floor. The innovative biologics portfolio (pegfilgrastim, adalimumab biosimilars) is globally positioned. The contrarian view: the market has not fully priced the 5-6 year pipeline of specialty and biologics launches, and at Rs 860, patient long-term investors are getting a meaningful discount to the intrinsic value of the pipeline.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Zydus_Lifesciences_Share_Price_Target\"><\/span><strong>Zydus Lifesciences Share Price Target<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p><a href=\"https:\/\/univest.in\/user\/log-in\">Subscribe to Univest Pro for Premium Stock Research and F&amp;O Setups<\/a><\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Short-Term_Target_3%E2%80%936_Months\"><\/span><strong>Short-Term Target (3\u20136 Months)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Support and short-term range: Rs 820-900. The stock may remain in this band while near-term headwinds persist.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"12-Month_Analyst_Target\"><\/span><strong>12-Month Analyst Target<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>The 12-month analyst consensus for Zydus Lifesciences is Rs 1,050-1,200, implying meaningful recovery potential from Rs 860.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Long-Term_Target_2027%E2%80%932028\"><\/span><strong>Long-Term Target (2027\u20132028)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>In a recovery scenario, the FY28 long-term target is Rs 1,400-1,600. Track live on <a href=\"https:\/\/univest.in\/screeners\">Univest Screener<\/a>.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>Zydus Lifesciences share price falling -20% from Rs 1,300 reflects sector headwinds and stock-specific pressures. The 12-month analyst consensus of Rs 1,050-1,200 implies recovery potential. Short-term support is Rs 820-900. For more analysis, visit<\/p><p><a href=\"https:\/\/univest.in\/blogs\">Univest Blogs<\/a><\/p><p><strong>Disclaimer: <\/strong>This article is for informational purposes only. Please conduct your own research and consult a SEBI-registered financial advisor before making any investment decisions.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"FAQs\"><\/span><strong>FAQs<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Q1_Why_is_Zydus_Lifesciences_share_price_falling\"><\/span><strong>Q1. Why is Zydus Lifesciences share price falling?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Zydus shares are falling due to the Asacol HD exclusivity period ending (Rs 400-500 crore revenue impact), US generics price erosion of 4-6% per year, insulin aspart FDA approval timeline uncertainty, EBITDA margin compression from 27.1% to 25.4%, and premium P\/E valuation facing pressure as exclusivities wind down.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Q2_What_is_the_Zydus_share_price_target_for_2026\"><\/span><strong>Q2. What is the Zydus share price target for 2026?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>The 12-month analyst consensus is Rs 1,050-1,200. MOFSL targets Rs 1,150, YES Securities targets Rs 1,200. Short-term support is Rs 800-820.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Q3_What_is_Zyduss_insulin_aspart_biosimilar\"><\/span><strong>Q3. What is Zydus&#8217;s insulin aspart biosimilar?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Zydus&#8217;s insulin aspart biosimilar (ZyTUS-B) is a recombinant human insulin analogue being developed for the US market. The US insulin biosimilar market is over $4 billion, and approval would be a meaningful revenue catalyst for Zydus&#8217;s long-term specialty pipeline.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Q4_What_is_Zyduss_US_business_revenue_contribution\"><\/span><strong>Q4. What is Zydus&#8217;s US business revenue contribution?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>US business contributes approximately 38% of Zydus Lifesciences&#8217; consolidated revenue, approximately Rs 7,500-8,000 crore annualised. It is the highest-margin segment and the key driver of overall EBITDA margin.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Q5_What_is_Zyduss_promoter_holding\"><\/span><strong>Q5. What is Zydus&#8217;s promoter holding?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Promoter (Pankaj Patel family) holds 74.9% of Zydus Lifesciences \u2014 a high and stable stake.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Q6_What_is_Zyduss_EBITDA_margin\"><\/span><strong>Q6. What is Zydus&#8217;s EBITDA margin?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Zydus reported EBITDA margin of 25.4% in Q3 FY26, declining from 27.1% a year ago. The compression reflects the exclusivity cliff and product mix dilution.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Q7_What_could_trigger_a_Zydus_share_price_recovery\"><\/span><strong>Q7. What could trigger a Zydus share price recovery?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>FDA approval of insulin aspart biosimilar, new US product launches filling the exclusivity gap, and India specialty branded business growing above 15% are the three primary recovery catalysts.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Q8_Is_Zydus_a_good_long-term_investment\"><\/span><strong>Q8. Is Zydus a good long-term investment?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Zydus has a strong track record, high promoter ownership, and a meaningful biosimilar pipeline. At Rs 860, it is near its one-year support. Long-term investors with 2-3 year horizon may find value, but near-term earnings visibility is limited. Consult a SEBI-registered advisor.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Recent_Article\"><\/span><strong>Recent Article<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p><a href=\"https:\/\/univest.in\/blogs\/mphasis-q4-results-2026\">Mphasis Q4 Results 2026: Date, Revenue Estimates, Key Catalysts &amp; Share Price Target<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/mastek-q4-results-2026\">Mastek Q4 Results 2026: Date, Revenue Estimates, Key Catalysts &amp; Share Price Target<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/cyient-q4-results-2026\">Cyient Q4 Results 2026: Date, Revenue Estimates, Key Catalysts &amp; Share Price Target<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/kpit-technologies-q4-results-2026\">KPIT Technologies Q4 Results 2026: Date, Revenue Estimates, Key Catalysts &amp; Share Price Target<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/zensar-technologies-q4-results-2026\">Zensar Technologies Q4 Results 2026: Date, Revenue Estimates, Key Catalysts &amp; Share Price Target<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Zydus Lifesciences is trading at Rs 860, down -20% from its 52-week high of Rs 1,300. The sustained decline in the Zydus Lifesciences share price reflects a combination of company-specific headwinds, sector pressures, and the broader macro overhang from the US 26% reciprocal tariff on Indian goods announced on April 2, 2026. This article explains<\/p>\n","protected":false},"author":29,"featured_media":68299,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[3818],"class_list":["post-68296","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-share-price-falling"],"metadata":{"_edit_lock":["1775716881:29"],"_last_editor_used_jetpack":["block-editor"],"rank_math_internal_links_processed":["1"],"rank_math_primary_category":["842"],"rank_math_seo_score":["78"],"rank_math_robots":["a:2:{i:0;s:8:\"nofollow\";i:1;s:7:\"noindex\";}"],"rank_math_title":["Why Is Zydus Lifesciences Share Price Falling? 2026"],"rank_math_description":["Zydus Lifesciences share price down 20% from Rs 1,300 high. US generics pricing pressure, Asacol exclusivity cliff, biosimilar timeline, FDA inspection risk. 2026 targets."],"rank_math_focus_keyword":["Zydus Lifesciences Share"],"_thumbnail_id":["68299"],"_edit_last":["29"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["7600"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/09120340\/ZYDUSLIFE_falling.jpg","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/68296","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/29"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=68296"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/68296\/revisions"}],"predecessor-version":[{"id":68315,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/68296\/revisions\/68315"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/68299"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=68296"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=68296"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=68296"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}